Charles Divita III Sells 17,805 Shares of Teladoc Health (NYSE:TDOC) Stock

Key Points

• Teladoc CEO Charles Divita III sold 17,805 shares at an average price of $6.10, generating $108,610.50. The sale covered tax withholding tied to vested equity awards, reducing his holdings by 3.68% to 465,535 shares.
• Teladoc shares rose 5.6% to $6.51, but the company remains unprofitable. Its latest quarter beat EPS estimates but missed revenue expectations, with revenue down 4% year over year.
• Analyst sentiment remains mixed, with a consensus rating of Hold and an average price target of $7.54. Institutional investors own 76.82% of the company’s stock.

Teladoc Health, Inc. (NYSE:TDOC - Get Free Report) CEO Charles III sold 17,805 shares of the business's stock in a transaction on Friday, September 11th. The shares were sold at an average price of $6.10, for a total transaction of $108,610.50. Following the completion of the transaction, the chief executive officer owned 465,535 shares in the company, valued at approximately $2,839,763.50. The trade was a 3.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Teladoc Health Stock Up 5.6%

TDOC traded up $0.35 during trading on Monday, reaching $6.51. 3,469,307 shares of the stock traded hands, compared to its average volume of 5,269,782. The stock's 50-day moving average is $7.51 and its 200 day moving average is $6.76. Teladoc Health, Inc. has a 12 month low of $4.40 and a 12 month high of $9.89. The stock has a market capitalization of $1.18 billion, a PE ratio of -6.57 and a beta of 2.12.

Teladoc Health (NYSE:TDOC - Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.04. Teladoc Health had a negative return on equity of 12.15% and a negative net margin of 7.13%.The firm had revenue of $606.93 million during the quarter, compared to analyst estimates of $615.44 million. During the same period last year, the company posted ($0.19) EPS. The business's quarterly revenue was down 4.0% on a year-over-year basis. Teladoc Health has set its Q3 2026 guidance at -0.300--0.200 EPS and its FY 2026 guidance at -1.000--0.750 EPS. As a group, equities research analysts anticipate that Teladoc Health, Inc. will post -0.9 EPS for the current year.

Institutional Investors Weigh In On Teladoc Health

A number of hedge funds have recently added to or reduced their stakes in the company. Monaco Asset Management SAM bought a new position in shares of Teladoc Health in the second quarter valued at approximately $26,864,000. ABS Investment Management LLC bought a new stake in Teladoc Health during the second quarter worth $1,513,154. Jupiter Asset Management Ltd. raised its position in Teladoc Health by 293.9% in the 4th quarter. Jupiter Asset Management Ltd. now owns 3,860,076 shares of the health services provider's stock valued at $27,021,000 after buying an additional 2,880,008 shares during the last quarter. Nano Cap New Millennium Growth Fund L P purchased a new stake in Teladoc Health in the 4th quarter valued at $1,225,000. Finally, Pale Fire Capital SE raised its position in Teladoc Health by 74.8% in the 1st quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider's stock valued at $18,522,000 after buying an additional 1,454,288 shares during the last quarter. Institutional investors and hedge funds own 76.82% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Citigroup reduced their price objective on shares of Teladoc Health from $11.00 to $7.50 and set a "neutral" rating for the company in a research report on Monday, August 3rd. Canaccord Genuity Group cut their target price on shares of Teladoc Health from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Thursday, July 30th. Weiss Ratings restated a "sell (d-)" rating on shares of Teladoc Health in a report on Wednesday, August 19th. Finally, Bank of America lifted their price target on shares of Teladoc Health from $9.00 to $10.50 and gave the company a "buy" rating in a research note on Tuesday, July 7th. Five investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $7.54.

About Teladoc Health

Teladoc Health, Inc is a virtual healthcare company that provides telehealth services and technology to individuals, employers, health plans, health systems and other organizations. Its platform enables patients to connect with healthcare professionals remotely through phone, video and digital tools, supporting access to medical care across a range of specialties.

The company's offerings include general medical consultations, mental health services through BetterHelp, expert medical opinions, chronic condition management and digital health programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.